Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Phase 2

Terminated

Brief Summary: This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG 337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal adenocarcinoma or other MET amplified solid tumors. The study is designed to estimate the objective response rate of AMG 337 by tumor type.

Detailed Description: This is a phase 2, multicenter, single arm, 2 cohort study to assess the safety, efficacy and pharmacokinetics of AMG 337 in MET amplified Gastric/esophageal adenocarcinoma or other solid tumors. Approximately 140 subjects will be enrolled to either Cohort 1 (subjects with MET amplified G/E adenocarcinoma with measurable tumor) or Cohort 2 (subjects with MET amplified solid tumors with measurable tumor/up to 10 subjects with MET amplified G/E adenocarcinoma with non-measurable tumor/up to 10 subjects who have received prior MET antibody therapy). All subjects will self-administer AMG 337 300 mg daily until disease progression or other protocol specified end of treatment criteria is met.

Tumor tissue, biomarkers, Pharmacokinetics and Patient reported Outcomes will all be assessed.

Tumor assessment by RECIST 1.1 will be followed during study treatment.

Recruitment & Eligibility

Inclusion Criteria

Able to daily self-administer AMG 337 orally as a whole capsule
Male or female 18 years of age or over.
Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid tumor (Cohort 2) for which subject has received prior therapy for advanced disease, for which no standard therapy exists, or subject refuses standard therapy
Tumor MET amplified by protocol-specified centralized testing.
Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1
(ECOG) Performance Status of 0, 1 or 2

Exclusion Criteria

Known central nervous system metastases
Candidate for curative surgery or definitive chemoradiation
Peripheral edema > grade 1
Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption
Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the opinion of the investigator or Amgen physician, if consulted, would not pose a risk to subject safety
Detectable Hepatitis C virus (indicative of active Hepatitis C)
Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment
Prior treatment with small molecule inhibitors of the MET pathway.

Other protocol defined inclusion criteria may apply.

Arm && Interventions

Group	Intervention	Description
Single arm	AMG 337	AMG 337 Monotherapy

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)	2.5 years	Determine antitumor activity of AMG 337 in subjects with MET amplified G/GEJ/E adenocarcinoma

Secondary Outcome Measures

Name	Time	Method
Progression free survival	2.5 years
Duration of response (cohort 1 and subjects with measurable disease at baseline in cohort 2)	2.5 years
Overall survival	2.5 years
Incidence and severity of adverse events and significant laboratory abnormalities	2.5 years
Pharmacokinetic parameters	2.5 years	Including, but not limited to, minimum (trough) concentrations at pre-dose times, maximum concentrations (C max), the time of C max (t max), and area under the plasma concentration - time curve (AUC).
Time to response (Cohort 1 and subjects with measurable disease at baseline in cohort 2)	2.5 years
Objective Response Rate (per RECIST v1.1) in subjects with other MET amplified solid tumors (subjects with measurable disease in cohort 2).	2.5 years	Determine antitumor activity of AMG 337 in subjects with other MET amplified solid tumors.
AMG 337 exposure and dose intensity	2.5 years